Results 1 to 10 of about 47,434 (363)
Role of ctDNA in Breast Cancer [PDF]
Cancers, 2022 Breast cancer is currently classified by immunohistochemistry. However, technological advances in the detection of circulating tumor DNA (ctDNA) have made new options available for diagnosis, classification, biological knowledge, and treatment selection.
Marta Sant +3 more
openaire +5 more sources
Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer [PDF]
Journal of Hematology & Oncology, 2019 Background Treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation sequencing technologies.
Hitendra Patel +7 more
doaj +3 more sources
Dynamics of ctDNA in patients with NSCLC
Annals of Oncology, 2019 Abstract Background For many years, researchers have tried to find more effective ways to find out if a person has cancer, and find it at an early stage, when it is most curable. One idea that is gaining popularity is called liquid biopsy. Methods From 2016 to 2018 we studied 1050 patients with non-small-cell lung cancer (NSCLC).
A.S. Zhabina +4 more
openalex +3 more sources
ctDNA identified in patients with CUP [PDF]
Nature Reviews Clinical Oncology, 2017 Peter Sidaway
openalex +3 more sources
ADN tumoral circulante en pacientes con cáncer: perspectivas desde el laboratorio clínico [PDF]
Advances in Laboratory MedicineEl análisis de ADN tumoral circulante (ctDNA) es un método no invasivo de gran relevancia para la caracterización molecular de los tumores sólidos, que aporta información valiosa sobre el perfil genético del cáncer. Actualmente, el análisis de mutaciones
Illana Francisco J. +13 more
doaj +2 more sources
Clinical utility of liquid biopsy next-generation sequencing for advanced non-small cell lung cancer in the Netherlands [PDF]
Scientific ReportsTumor molecular profiling is essential for therapeutic management of advanced non-small cell lung cancer (NSCLC). However, a biopsy is not for every patient possible and can have complications, which plasma derived circulating tumor DNA (ctDNA) analysis ...
Tessa J. J. de Bitter +14 more
doaj +2 more sources
ctDNA as a biomarker of progression in oesophageal adenocarcinoma [PDF]
ESMO Open, 2021 Abstract Background: The incidence of oesophageal adenocarcinoma (OAC) is rapidly increasing and despite improvements in treatment, the five-year survival rate remains poor. Prognostic biomarkers that address the genomic heterogeneity in this highly complex disease will aid the development of precision therapeutics and improve patient survival.
Vanessa F. Bonazzi +10 more
openaire +3 more sources
Description of the calf thymus DNA-malathion complex behavior by multi-spectroscopic and molecular modeling techniques: EMF at low and high frequency approaches [PDF]
Iranian Journal of Basic Medical Sciences, 2021 Objective(s): Small molecules can bind to DNA via covalent or non-covalent interactions, which results in altering or inhibiting the function of DNA. Thus, understanding the interaction patterns of medicines or other small molecules can be very crucial ...
Tahmineh Sohrabi +5 more
doaj +1 more source
Circulating Tumor DNA (ctDNA) in Kidney Cancer: A Narrative Review
Société Internationale d’Urologie Journal, 2023 Circulating tumor DNA (ctDNA) has been investigated as a potential noninvasive biomarker for disease prognostication, monitoring, and treatment selection in various tumor types, including renal cell carcinoma (RCC). In this narrative review,
Wesley Yip, A. Ari Hakimi
doaj +1 more source
Liquid biopsy in CNS tumors: Current status & future perspectives
Indian Journal of Pathology and Microbiology, 2022 Precise classification of central nervous system (CNS) malignancies is vital for the treatment and prognostication. Identification of noninvasive markers can be of importance to guide treatment decisions and in monitoring treatment response.
Nuzhat Husain +3 more
doaj +1 more source